cefditoren and fropenem

cefditoren has been researched along with fropenem* in 6 studies

Other Studies

6 other study(ies) available for cefditoren and fropenem

ArticleYear
[Epidemiological study on patients with pneumococcal respiratory tract infection in a Japanese health facility during the past year].
    The Japanese journal of antibiotics, 2001, Volume: 54 Suppl B

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Chronic Disease; Clarithromycin; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Lactams; Male; Middle Aged; Ofloxacin; Pneumococcal Infections; Respiratory Tract Infections; Streptococcus pneumoniae; Time Factors

2001
[Comparative study on bacterial eradication rate and clinical efficacy of CDTR, CFPN, and FRPM for treatment of children with otitis media and lower respiratory tract infection due to Streptococcus pneumoniae and Haemophilus influenzae].
    The Japanese journal of antibiotics, 2001, Volume: 54 Suppl B

    Topics: Ampicillin Resistance; Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Child; Child, Preschool; Community-Acquired Infections; Haemophilus Infections; Haemophilus influenzae; Humans; Infant; Lactams; Otitis Media; Penicillin Resistance; Pneumococcal Infections; Respiratory Tract Infections; Retrospective Studies; Streptococcus pneumoniae; Treatment Outcome

2001
[Study on Streptococcus pneumoniae isolated from infants in widely-separated primary care facilities in Japan].
    The Japanese journal of antibiotics, 2001, Volume: 54 Suppl B

    Topics: Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Child Day Care Centers; Child, Preschool; Drug Resistance, Bacterial; Humans; Infant; Japan; Lactams; Otitis Media; Penicillin G; Serotyping; Siblings; Streptococcus pneumoniae

2001
[In vitro activity of faropenem against beta-lactamase producing clinical isolates].
    The Japanese journal of antibiotics, 2000, Volume: 53, Issue:3

    Each 20 strains of beta-lactamase producing methicillin susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, Moraxella (Branhamella) catarrhalis, and Bacteroides fragilis group were used as the test strains. Drug susceptibility of these strains to faropenem (FRPM), cefdinir, cefditoren, cefcapene, cefteram, cefaclor, and ampicillin was determined by an agar dilution method according to the NCCLS guideline M100-S9. beta-Lactamase activity of the test strains was determined by a spectrophotometric method. In the present study, FRPM was highly active against beta-lactamase-producing strains, and no close correlation was found between the MICs of FRPM for the test strains and their beta-lactamase activities. These results suggest that FRPM has potential in successful application for the treatment of infectious diseases with various types of bacterial pathogens including beta-lactamase producing strains.

    Topics: Anti-Bacterial Agents; Bacteria; beta-Lactamases; beta-Lactams; Cefdinir; Cephalosporins; Drug Resistance, Microbial; Humans; Lactams; Microbial Sensitivity Tests

2000
[In vitro antibacterial activity of faropenem, a novel oral penem antibiotic, against enterohemorrhagic Escherichia coli O157 strains].
    The Japanese journal of antibiotics, 1999, Volume: 52, Issue:8

    Against enterohemorrhagic Escherichia coli (EHEC) O157 clinically isolated, the effects of faropenem (FRPM), a novel oral penem antibiotic, on the MICs, bactericidal activity, verotoxin (VT)-release, and lipopolysaccharide (LPS)-release were investigated in vitro and compared with those of other types of antibacterial agents. The MICs of FRPM in aerobic and anaerobic culture condition, were 0.78 and 0.39 microgram/ml, respectively. In aerobic condition, FRPM was more active than ampicillin, amoxicillin (AMPC), fosfomycin (FOM), kanamycin (KM), minocycline (MINO), and clarithromycin (CAM), but was slightly less active than cefdinir (CFDN), cefditoren (CDTR), and norfloxacin (NFLX) against O157 clinical isolates. In anaerobic condition, however, FRPM showed as strong activity as CFDN, CDTR, and NFLX. FOM, NFLX, and KM as well as the beta-lactams including FRPM indicated the powerful bactericidal activity against one strain of O157 clinical isolates. The effects of MINO and CAM were bacteriostatic. FOM and the beta-lactams including FRPM promoted verotoxin type 1 (VT1)-release, but rather suppressed verotoxin type 2 (VT2)-release from the same isolate. NFLX, however, promoted VT1-release and vast amount of VT2-release. In the case of KM, MINO, and CAM, the release suppression of both VT1 and VT2 was observed. FRPM, AMPC, and FOM had very weak activity on LPS-release, while CFDN, CDTR, and NFLX released a large amount of LPS from the strain. KM, MINO, and CAM had relatively weak activity. In these in vitro experiments, FRPM demonstrated the effective profile to the treatment for EHEC infection, except for the effect on VT1-release. These results suggest the possibility that FRPM shows good clinical efficacy for EHEC infection.

    Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; Bacterial Toxins; beta-Lactams; Cefdinir; Cephalosporins; Clarithromycin; Escherichia coli O157; Fosfomycin; Kanamycin; Lactams; Microbial Sensitivity Tests; Minocycline; Norfloxacin; Shiga Toxin 1

1999
[Investigation of the antibacterial activity of faropenem against Streptococcus pneumoniae].
    The Japanese journal of antibiotics, 1999, Volume: 52, Issue:9

    We evaluated the antibacterial activity of faropenem against penicillin-susceptible Streptococcus pneumoniae (PSSP) and penicillin-resistant S. pneumoniae (PRSP). It was shown that the minimum inhibitory concentrations against 90% of the clinically isolated strains (MIC90) of faropenem, penicillin G, cefaclor, cefcapene, and cefditoren against PSSP were 0.032, 0.063, 2, 0.25, and 0.125 micrograms/ml, respectively. While those against PRSP were 0.5, 2, > 128, 1, and 1 micrograms/ml, respectively. Furthermore, we evaluated the bactericidal activity, at the level of 1/4, 1, and 4 MIC, of faropenem and the above four reference antibacterial agents against PSSP and PRSP. Against PSSP No. 127, a sensitive strain to both penicillin G and cefcapene, faropenem showed almost the same bactericidal activity as those of reference agents. Against PSSP No. 108, a penicillin-susceptible and cephem-resistant strain, and PRSP No. 57, a resistant strain to both of penicillin and cephem, faropenem of 1 MIC showed bactericidal activity, but reference agents needed 4 MIC to show bactericidal activity.

    Topics: Anti-Bacterial Agents; beta-Lactams; Cefaclor; Cephalosporins; Drug Resistance, Microbial; Lactams; Penicillin G; Penicillin Resistance; Streptococcus pneumoniae

1999